中国神经再生研究(英文版) ›› 2024, Vol. 19 ›› Issue (4): 788-799.doi: 10.4103/1673-5374.382220

• 综述:脑损伤修复保护与再生 • 上一篇    下一篇

大麻素和内源性大麻素作为治疗神经系统疾病的药物:临床前模型和临床研究

  

  • 出版日期:2024-04-15 发布日期:2023-09-15

Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies

R. Scott Duncan1, Sean M. Riordan1, Matthew C. Gernon1, Peter Koulen1, 2, *   

  1. 1Department of Ophthalmology, School of Medicine, University of Missouri, Kansas, MO, USA; 2Department of Biomedical Sciences, School of Medicine, University of Missouri, Kansas, MO, USA
  • Online:2024-04-15 Published:2023-09-15
  • Contact: Peter Koulen, PhD, koulenp@umkc.edu.
  • Supported by:
    This work was supported in part by grants from the National Institute on Aging and National Eye Institute [EY030747 (3R01EY030747-02S2) and EY031248 (3R01EY031248-02S1)] of the National Institutes of Health (to PK). Additional support by the Felix and Carmen Sabates Missouri Endowed Chair in Vision Research and the Vision Research Foundation of Kansas City is gratefully acknowledged.

摘要: https://orcid.org/0000-0002-0428-4288 (Peter Koulen)

Abstract: Cannabinoids are lipophilic substances derived from Cannabis sativa that can exert a variety of effects in the human body. They have been studied in cellular and animal models as well as in human clinical trials for their therapeutic benefits in several human diseases. Some of these include central nervous system (CNS) diseases and dysfunctions such as forms of epilepsy, multiple sclerosis, Parkinson’s disease, pain and neuropsychiatric disorders. In addition, the endogenously produced cannabinoid lipids, endocannabinoids, are critical for normal CNS function, and if controlled or modified, may represent an additional therapeutic avenue for CNS diseases. This review discusses in vitro cellular, ex vivo tissue and in vivo animal model studies on cannabinoids and their utility as therapeutics in multiple CNS pathologies. In addition, the review provides an overview on the use of cannabinoids in human clinical trials for a variety of CNS diseases. Cannabinoids and endocannabinoids hold promise for use as disease modifiers and therapeutic agents for the prevention or treatment of neurodegenerative diseases and neurological disorders.

Key words: anandamide, cannabidiol, cannabinoid, endocannabinoid, epilepsy, multiple sclerosis, neurodegeneration, neuroprotection, tetrahydrocannabinol